ADMA Biologics Faces Securities Fraud Class Action Over Revenue Claims

The complaint alleges that ADMA executives misled shareholders by failing to disclose critical operational issues during the specified period. Specifically, the litigation claims the company engaged in an undisclosed related party transaction and utilized channel stuffing to artificially inflate revenue figures. These practices, according to the filing, were exacerbated by a lack of adequate internal controls, rendering the company’s public statements regarding its business prospects materially deceptive.

Shareholders who purchased ADMA stock during this window are eligible to participate in the class action. While affected investors may choose to retain their own counsel or remain absent members of the class, those interested in serving as lead plaintiff must coordinate with the Law Offices of Frank R. Cruz before the mid-August deadline. The firm is currently collecting inquiries from investors regarding their share purchases and legal standing in the ongoing action.